Novartis
Basel, Switzerland
East Hanover, New Jersey, United States
with other locations globally
United States
Website: http://www.novartis.com/
About Novartis
At Novartis, we are driven by a single mission: to discover new ways to improve and extend people’s lives. Through science-based innovation we address some of society’s most challenging healthcare issues. Working to discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Novartis focuses on innovative patent-protected medicines, generics and eye care products – segments where we have global reach and strong relations with our customers. Research and development (R&D) sits at the core of our business and central to our strategy. Our global organizations for manufacturing, business services and other functions help increase efficiency and promote excellence.
Reimagine what you could do at Novartis.
1632 articles with Novartis
-
On Monday, N.C. Gov. Roy Cooper announced the expansion to the company’s Durham facility that was first announced in May 2018. It's expected to provide up to 200 additional jobs.
-
Novartis announced that the FDA approved the company’s Egaten to treat fascioliasis in patients six years of age and older. Novartis also inked a multi-target and multi-year collaboration with AbCellera.
-
There’s no doubt that drug prices, particularly sky-high prices for new biologics and companies jacking up the prices of older drugs, is a problem. And it’s definitely a political issue, especially now that candidates are declaring their plans to run for president in 2020.
-
Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.
-
London-based Clinigen Group pc will now have full rights to Proleukin (aldesleukin, human recombinant interleukin-2). This morning, the U.K.-based pharmaceutical and services company struck a deal with Novartis to acquire the U.S. rights to the metastatic renal cell carcinoma treatment.
-
As Britain’s plans to leave the European Union—Brexit—stagger toward the March 29 deadline, the UK biopharma industry is taking stock of the likely impact.
-
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the pro...
-
IDEA Pharma recently published its “Pharmaceutical Innovation Index 2018.” This report ranks biopharma companies on their ability to bring products from Phase I/II to market and then successfully commercialize them. They used a variety of sources, including company websites, third-party instituti...
-
Four months after getting the green light in the U.K. for treatment of children with acute lymphoblastic leukemia (ALL), Novartis’ CAR-T treatment Kymriah, known as Tisagenlecleucel in the U.K., has gained approval for treatment of adults with diffuse large B-cell lymphoma (DLBCL).
-
NICE approves Novartis’ CAR-T therapy Kymriah® (tisagenlecleucel)▼ for DLBCL in adults following commercial agreement with NHS England
2/1/2019
Novartis today announced that Kymriah® (tisagenlecleucel) treatment for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments is to be made available for NHS patients in England and Wales following appraisal by NICE (National Institute for Health and Care Excellence).
-
Novartis Chief Executive Officer Vas Narasimhan said 2018 was a year of reimagining for Switzerland-based Novartis. It was a year when the company focused its capital and resourced on developing breakthrough medicines.
-
Novartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
1/28/2019
Novartis announced today results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate-to-severe plaque psoriasis (PsO) treated with Cosentyx® (secukinumab) 300 mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnaire as early as Week 4 when compared to placebo in patients who reported problems at baseline
-
As the United Kingdom nears closer and closer to exiting the European Union without a deal, drug manufacturers like Novartis are preparing contingencies for how they will continue to provide medications, many of them life-saving, for patients in the U.K.
-
Philogen Announces Collaboration
1/23/2019
Philogen S.p.A. announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics.
-
Novartis and Oxford will use artificial intelligence and advanced analytics to identify early predictors of inflammatory diseases.
-
Sandoz Inc. launches SYMJEPI™ (epinephrine) in the US
1/16/2019
Sandoz Inc. (Sandoz), a Novartis division, announced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.
-
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
-
Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.
-
“Think of it as an installment plan that’s then tied to how well the therapy works,” Mark Trusheim, strategic director of the MIT Center for Biomedical Innovation’s NEWDIGS program, told Business Insider. “This would be a car loan but you’ve still got to see if the car is going to work.”
-
Swiss pharma giant Novartis has found itself at the center of a legal battle that could determine if the company engaged in a research project that was a kickback in disguise.